Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis.
Doriana LandiFrancesca BovisAlfonso GrimaldiPietro Osvaldo AnnovazziAntonio BertolottoAlessia BianchiGiovanna BorrielloVincenzo Brescia MorraSebastiano BucelloMaria Chiara BuscarinuFrancesca CaleriMarco Alfonso CapobiancoRuggero CapraMaria CellerinoDiego CentonzeRaffaella CerquaClara Grazia ChisariMarinella ClericoEleonora CoccoGaia ColaCinzia CordioliErica CurtiAlessandro d'AmbrosioEmanuele D'AmicoGiovanna De LucaMassimiliano Di FilippoSonia Di LemmeRoberta FantozziDiana FerraroElisabetta FerraroAntonio GalloClaudio GasperiniFranco GranellaMatilde IngleseRoberta LanzilloLorena LoreficeGiacomo LusSimona MalucchiMonica MargoniGiorgia MataluniMassimiliano MirabellaLucia MoiolaCarolina Gabri NicolettiViviana NocitiFrancesco PattiFederica PinardiEmilio PortaccioCarlo PozzilliPaolo RagoneseSarah RasiaGiuseppe SalemiElisabetta SignorielloFrancesca VitettaRocco TotaroMaria Pia SormaniMaria Pia AmatoGirolama Alessandra MarfiaPublished in: Journal of neurology, neurosurgery, and psychiatry (2022)
Our findings indicate that in women with MS treated with NTZ before conception, continuation of NTZ throughout pregnancy and its early resumption after delivery mitigate the risk of clinical and radiological reactivation. This approach has no major impact on newborns' outcomes.